In a nutshell This study investigated the effectiveness of biofeedback therapy in rectal cancer patients with anterior resection syndrome (ARS) after rectal surgery. Researchers reported that this therapy can improve the anal function after rectal surgery. Some background ARS is a common condition after rectal surgery. Patients with this condition...
Read MoreHow do I manage my side effects for better quality of life? Patient Power founder and host, Andrew Schorr, facilitates a dialogue between advanced prostate cancer experts, Dr. William Catalona, Dr. Russell Szmulewitz of University of Chicago Medical Center, and Judith Paice, PhD, RN to discuss managing and communicating treatment side effects. ...
Read More
In a nutshell This study examined the effect of androgen deprivation therapy (ADT) on clinical depression. Authors reported that ADT increased the risk of depression and the need for psychiatric treatment. The risk of depression increased with duration of ADT. Some background ADT is a type of hormone therapy commonly used to treat prostate cancer....
Read MoreIn a nutshell This study compared immediate and delayed androgen deprivation therapy (ADT) for men with relapsed or non-curable prostate cancer. Authors reported improved survival and disease progression with immediate ADT. Some background ADT is a type of hormone therapy used to treat prostate cancer. It targets the production of male hormones...
Read More
In a nutshell This study compared the safety and effectiveness of afatinib (Gilotrif) and erlotinib (Tarceva) as second-line treatments for advanced squamous cell carcinoma (SCC). Authors reported improved survival and disease progression with afatinib compared to erlotinib. Both treatments were associated with a good safety profile. Some background...
Read More
In a nutshell This study investigated the risk of disease recurrence after prostate surgery based on surgical margins. Authors reported an increased risk of disease recurrence among men with close surgical margins. Some background Removal of the prostate gland is a common treatment of localized (confined) prostate cancer. Prostate surgery is...
Read More
In a nutshell This study investigated cabozantinib (Cometriq), an anti-angiogenic drug, in the treatment of advanced and progressing prostate cancer. Researchers report preliminary evidence for cabozantinib in reducing disease progression and cancer pain. Some background Tumors need to be able to grow new blood vessels in order to grow....
Read MoreIn a nutshell This phase 2 trial aims to evaluate combinations of hormone therapies, a steroid drug, an immunotherapy drug, and chemotherapy in the treatment of metastatic castration-resistant prostate cancer. The main outcome to be investigated is overall survival (time from treatment until death from any cause). The trial is recruiting in Houston,...
Read More
Patient advocate Jeff Folloder conducts an in-depth discussion on emerging immunotherapy approaches for advanced prostate cancer with MD Anderson Cancer Center experts, Dr. Sumit Subudhi and Dr. Jeri Kim. Walking us through developing treatments, including vaccines and checkpoint inhibitors/immune modulators, these experts refer to today as...
Read More
In a nutshell This review examined whether the neutrophil-to-lymphocyte ratio (NLR) was useful in predicting the prognosis of prostate cancer. Researchers reported a strong link between the NLR and overall survival and cancer recurrence. Some background Neutrophils are cells that are involved in inflammation (reaction to injury or infection)....
Read More
In a nutshell This review evaluated first-line treatments for metastatic castration-resistant prostate cancer (mCRPC). Authors recommend chemotherapy with docetaxel (Taxotere) for mCRPC with high tumor burden or at high risk of rapid progression. Alternative hormonal therapy or chemotherapy may be effective in other cases. Some background...
Read More
In a nutshell This review compared the potential risks and benefits of two hormone therapies available for androgen deprivation therapy (ADT). Authors concluded that GnRH antagonists offer a safe and effective alternative to GnRH agonists. Some background ADT is a type of hormone therapy commonly used to treat advanced prostate cancer. ADT targets...
Read More
